Zymeworks (ZYME) Cash & Equivalents (2021 - 2026)

Zymeworks' Cash & Equivalents history runs 6 years deep, the most recent figure standing at $244.3 million for Q1 2026.

• In Q1 2026, Cash & Equivalents rose 220.56% year-over-year to $244.3 million; the TTM figure through Mar 2026 stood at $244.3 million (up 220.56% YoY), while the FY2025 annual figure was $41.2 million, down 37.74% from the prior year.
• Cash & Equivalents came in at $244.3 million for Q1 2026 at Zymeworks, up from $41.2 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $400.9 million in Q4 2022 to a low of $41.2 million in Q4 2025.
• A 5-year average of $131.4 million and a median of $98.3 million in 2025 frame the typical range for Cash & Equivalents.
• Across the five-year window, Cash & Equivalents plunged 60.7% in 2023 and soared 220.56% in 2026, its largest moves.
• Zymeworks' Cash & Equivalents stood at $400.9 million in 2022, then slumped by 60.7% to $157.6 million in 2023, then slumped by 58.05% to $66.1 million in 2024, then tumbled by 37.74% to $41.2 million in 2025, then jumped by 493.54% to $244.3 million in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $244.3 million, $41.2 million, and $64.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison